Impact of COVID-19 on venture-backed biotech companies – Part 2: Investment and cash flow
par Adrian Toutoungi et Josef Fuss
Impact of COVID-19 on venture-backed biotech companies – Part 1: Operational issues
par Adrian Toutoungi et Josef Fuss
NHS can procure drugs for use outside of their approved indications if it's cheaper, court says
Everything biologic and biosimilar in-house counsel need to know about COVID-19
par plusieurs auteurs
Patent pools: an easy licensing option for COVID-19 drugs and SARS CoV 2 vaccines?
An exploration of patent pools, R&D and current initiatives.
par Dr. Anja Lunze, LL.M. et Dr. Jan Phillip Rektorschek
2 de 6 Publications
Termination, force majeure and frustration – international perspectives on the life sciences sector
par plusieurs auteurs
COVID-19 and life sciences M&A
par plusieurs auteurs
Marketing authorisation and clinical testing of new drugs
Competition law issues shaping the pharmaceutical sector
par Paolo Palmigiano et Louisa Penny
Special approvals of the Federal Institute for Drugs and Medical Devices for the distribution of medical devices and FFP breathing masks without an expiration valve